RAPTOR

An Eighteen-Month, Two-Arm, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Adult Patients with Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion …

KESTREL

A Two-year, Three-arm, Randomized, Double-masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Adult Patients with Visual Impairment Due to Diabetic Macular Edema (KESTREL) SPONSOR: Novartis Pharmaceuticals CLINICALTRIALS.GOV